UroGen Pharma (URGN) Amortization of Deferred Charges (2020 - 2026)
UroGen Pharma (URGN) posted Amortization of Deferred Charges of $577000.0 for Q1 2026, down 4.47% on a QoQ basis from $604000.0 in Q4 2025, and up 35.76% year-over-year from $425000.0 in Q1 2025.
UroGen Pharma (URGN) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
UroGen Pharma's Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $577000.0 for Q1 2026.
- Quarterly Amortization of Deferred Charges rose 35.76% year-over-year to $577000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (up 114.04% YoY) and the FY2025 annual result came in at $2.1 million, up 145.51% from the prior year.
- Amortization of Deferred Charges was $577000.0 for Q1 2026 at UroGen Pharma, down from $604000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $604000.0 in Q4 2025 and bottomed at $193000.0 in Q2 2024.
- A 5-year average of $313764.7 and a median of $234000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges retreated 16.6% — and 2025, when it soared 182.32%.
- UroGen Pharma's Amortization of Deferred Charges stood at $214000.0 in 2022, then climbed by 9.35% to $234000.0 in 2023, then gained by 1.71% to $238000.0 in 2024, then surged by 153.78% to $604000.0 in 2025, then retreated by 4.47% to $577000.0 in 2026.
- Business Quant data shows URGN's Amortization of Deferred Charges at $577000.0 in Q1 2026, $604000.0 in Q4 2025, and $559000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | UroGen Pharma | 2.05 Bn | 1.91 Bn | 46.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 577,000.00 |
| Mar 31, 2026 | 577,000.00 |
| Dec 31, 2025 | 604,000.00 |
| Dec 31, 2025 | 604,000.00 |
| Sep 30, 2025 | 559,000.00 |
| Sep 30, 2025 | 559,000.00 |
| Jun 30, 2025 | 516,000.00 |
| Jun 30, 2025 | 516,000.00 |
| Mar 31, 2025 | 425,000.00 |
| Mar 31, 2025 | 425,000.00 |
| Dec 31, 2024 | 238,000.00 |
| Dec 31, 2024 | 238,000.00 |
| Sep 30, 2024 | 198,000.00 |
| Sep 30, 2024 | 198,000.00 |
| Jun 30, 2024 | 193,000.00 |
| Jun 30, 2024 | 193,000.00 |
| Mar 31, 2024 | 228,000.00 |
| Mar 31, 2024 | 228,000.00 |
| Dec 31, 2023 | 234,000.00 |
| Dec 31, 2023 | 234,000.00 |